Cargando…

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution

Astatine-211 ((211)At)-labeled phenylalanine is expected to be a promising agent for targeted alpha-particle therapy for the treatment of patients with glioma. The existing reactions to prepare the labeled compound usually require organic solvents and metals that are toxic and hazardous to the envir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirakami, Yoshifumi, Watabe, Tadashi, Obata, Honoka, Kaneda, Kazuko, Ooe, Kazuhiro, Liu, Yuwei, Teramoto, Takahiro, Toyoshima, Atsushi, Shinohara, Atsushi, Shimosegawa, Eku, Hatazawa, Jun, Fukase, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217504/ https://www.ncbi.nlm.nih.gov/pubmed/34155314 http://dx.doi.org/10.1038/s41598-021-92476-6

Ejemplares similares

Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
por: Kato, Hiroki, et al.
Publicado: (2021)

Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
por: Watabe, Tadashi, et al.
Publicado: (2022)

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
por: Huang, Xuhao, et al.
Publicado: (2022)

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
por: Watabe, Tadashi, et al.
Publicado: (2022)

Enhancing the Therapeutic Effect of 2-(211)At-astato-α-methyl-L-phenylalanine with Probenecid Loading
por: Hanaoka, Hirofumi, et al.
Publicado: (2021)

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
por: Aso, Ayaka, et al.
Publicado: (2023)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
por: Watabe, Tadashi, et al.
Publicado: (2023)

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with (211)At Using Implanted Mouse Tumor
por: Yonekura, Yoshiharu, et al.
Publicado: (2022)

Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
por: Watabe, Tadashi, et al.
Publicado: (2021)

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
por: Kaneda-Nakashima, Kazuko, et al.
Publicado: (2022)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

Multi-modal 3D imaging of radionuclides using multiple hybrid Compton cameras
por: Omata, Akihisa, et al.
Publicado: (2022)

Performance demonstration of a hybrid Compton camera with an active pinhole for wide-band X-ray and gamma-ray imaging
por: Omata, Akihisa, et al.
Publicado: (2020)

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
por: Lindegren, Sture, et al.
Publicado: (2020)

Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018)

Improved Stability and Practicality for Synthesis of 4-Borono-2-[(18)F]fluoro-l-phenylalanine by Combination of [(18)O]O(2) Single-Use and [(18)F]CH(3)COOF Labeling Agents
por: Naka, Sadahiro, et al.
Publicado: (2022)

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
por: Vaidyanathan, G., et al.
Publicado: (1997)

Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)

Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates
por: Teze, David, et al.
Publicado: (2017)

Simulation of the distribution of astatine-211 solution dispersion in a lab room
por: Kubo, Hitoshi, et al.
Publicado: (2021)

Astatine-211 based radionuclide therapy: Current clinical trial landscape
por: Albertsson, Per, et al.
Publicado: (2023)

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
por: Makvandi, Mehran, et al.
Publicado: (2022)

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
por: Timperanza, Chiara, et al.
Publicado: (2023)

Bis[3-(dihydroxyboryl)anilinium] sulfate
por: Vega, Araceli, et al.
Publicado: (2010)

Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-(18)F-fluoro-phenylalanine (FBPA) PET study
por: Isohashi, Kayako, et al.
Publicado: (2016)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
por: Li, Huizi Keiko, et al.
Publicado: (2018)

tert-Butyl 2-(dihydroxyboryl)pyrrole-1-carboxylate
por: Klis, Tomasz, et al.
Publicado: (2008)

Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
por: Hauck, M. L., et al.
Publicado: (1998)

Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
por: Katayama, Daisuke, et al.
Publicado: (2021)

Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-(211)At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
por: Ohshima, Yasuhiro, et al.
Publicado: (2019)

Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets
por: O’Hara, Matthew J., et al.
Publicado: (2019)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Optimization of [(11)C]methionine PET study: appropriate scan timing and effect of plasma amino acid concentrations on the SUV
por: Isohashi, Kayako, et al.
Publicado: (2013)

CT-Based Attenuation Correction in Brain SPECT/CT Can Improve the Lesion Detectability of Voxel-Based Statistical Analyses
por: Kato, Hiroki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bm14dqsd73v46o0fdpehl0em2n